480 related articles for article (PubMed ID: 16444869)
21. Nitric oxide synthase inhibitors and cerebral vasospasm.
Jung CS
Acta Neurochir Suppl; 2011; 110(Pt 1):87-91. PubMed ID: 21116921
[TBL] [Abstract][Full Text] [Related]
22. Severely decreased activity of placental dimethylarginine dimethylaminohydrolase in pre-eclampsia.
Anderssohn M; Maass LM; Diemert A; Lüneburg N; Atzler D; Hecher K; Böger RH
Eur J Obstet Gynecol Reprod Biol; 2012 Apr; 161(2):152-6. PubMed ID: 22285683
[TBL] [Abstract][Full Text] [Related]
23. Asymmetric dimethylarginine, an endogenous NOS inhibitor, is actively metabolized in rat erythrocytes.
Yokoro M; Suzuki M; Murota K; Otsuka C; Yamashita H; Takahashi Y; Tsuji H; Kimoto M
Biosci Biotechnol Biochem; 2012; 76(7):1334-42. PubMed ID: 22785485
[TBL] [Abstract][Full Text] [Related]
24. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
25. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production.
Pope AJ; Karuppiah K; Cardounel AJ
Pharmacol Res; 2009 Dec; 60(6):461-5. PubMed ID: 19682581
[TBL] [Abstract][Full Text] [Related]
26. Effect of selected drugs on plasma asymmetric dimethylarginine (ADMA) levels.
Trocha M; Szuba A; Merwid-Lad A; Sozański T
Pharmazie; 2010 Aug; 65(8):562-71. PubMed ID: 20824955
[TBL] [Abstract][Full Text] [Related]
27. Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease?
Bouras G; Deftereos S; Tousoulis D; Giannopoulos G; Chatzis G; Tsounis D; Cleman MW; Stefanadis C
Curr Top Med Chem; 2013; 13(2):180-200. PubMed ID: 23470077
[TBL] [Abstract][Full Text] [Related]
28. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases.
Böger RH; Sydow K; Borlak J; Thum T; Lenzen H; Schubert B; Tsikas D; Bode-Böger SM
Circ Res; 2000 Jul; 87(2):99-105. PubMed ID: 10903992
[TBL] [Abstract][Full Text] [Related]
29. The ADMA/DDAH/NO pathway in human vein endothelial cells exposed to arsenite.
Osorio-Yáñez C; Chin-Chan M; Sánchez-Peña LC; Atzatzi-Aguilar OG; Olivares-Reyes JA; Segovia J; Del Razo LM
Toxicol In Vitro; 2017 Aug; 42():281-286. PubMed ID: 28502835
[TBL] [Abstract][Full Text] [Related]
30. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
31. Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity.
Jiang JL; Zhang XH; Li NS; Rang WQ; Feng-Ye ; Hu CP; Li YJ; Deng HW
Cardiovasc Drugs Ther; 2006 Aug; 20(4):281-94. PubMed ID: 16897158
[TBL] [Abstract][Full Text] [Related]
32. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine.
Yin QF; Fu SH; He P; Xiong Y
Atherosclerosis; 2007 Jan; 190(1):53-61. PubMed ID: 16533509
[TBL] [Abstract][Full Text] [Related]
33. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
34. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells.
Jia SJ; Jiang DJ; Hu CP; Zhang XH; Deng HW; Li YJ
Vascul Pharmacol; 2006 Mar; 44(3):143-8. PubMed ID: 16309971
[TBL] [Abstract][Full Text] [Related]
35. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
Palm F; Onozato ML; Luo Z; Wilcox CS
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3227-45. PubMed ID: 17933965
[TBL] [Abstract][Full Text] [Related]
36. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials.
Szuba A; Podgórski M
Pharmacol Rep; 2006; 58 Suppl():16-20. PubMed ID: 17332667
[TBL] [Abstract][Full Text] [Related]
37. Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis.
Segarra G; Cortina B; Mauricio MD; Novella S; Lluch P; Navarrete-Navarro J; Noguera I; Medina P
World J Gastroenterol; 2016 Dec; 22(48):10545-10556. PubMed ID: 28082806
[TBL] [Abstract][Full Text] [Related]
38. The DDAH-ADMA-NOS pathway.
Leiper JM
Ther Drug Monit; 2005 Dec; 27(6):744-6. PubMed ID: 16404814
[TBL] [Abstract][Full Text] [Related]
39. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury.
Stühlinger MC; Conci E; Haubner BJ; Stocker EM; Schwaighofer J; Cooke JP; Tsao PS; Pachinger O; Metzler B
Cardiovasc Res; 2007 Jul; 75(2):417-25. PubMed ID: 17559823
[TBL] [Abstract][Full Text] [Related]
40. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
Lin KY; Ito A; Asagami T; Tsao PS; Adimoolam S; Kimoto M; Tsuji H; Reaven GM; Cooke JP
Circulation; 2002 Aug; 106(8):987-92. PubMed ID: 12186805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
